How to Manage Estrogen on TRT

Your testosterone goes in, your estradiol goes up, and your provider hands you a prescription for anastrozole. That sequence happens thousands of times a day in men's health clinics, and it skips over an entire layer of biology that explains why the estradiol went up in the first place.

To understand why that matters, you need the full chain first.

Your body makes estradiol from testosterone using an enzyme called aromatase, which is technically named CYP19A1 and works by catalyzing a three-step chemical reaction that converts androgens into estrogens. In men, roughly 80% of circulating estradiol comes from this peripheral conversion happening out in your tissues, primarily your fat tissue, and only about 20% comes directly from your testes. So when you're on TRT and your estradiol rises, the driving force is almost never that you have too much aromatase activity in some abstract sense. The driving force is something specific, and that specificity is what makes the whole picture manageable without a drug.

Aromatase conversion is what's called substrate-driven, which means the more raw material you give the enzyme, the more estrogen it produces. Inject 200mg of testosterone once a week and you get a large spike in circulating testosterone peaking roughly 24 to 48 hours after injection, and because aromatase works on whatever substrate is present, estradiol trails that peak by about one to two days and then climbs. Take that same 200mg and split it into two injections across the week and the individual peaks are smaller, the substrate load at any given moment is lower, and the estradiol response is correspondingly flattened. Testosterone cypionate has an elimination half-life of approximately 4.5 days and a mean residence time of approximately 8.5 days, which means weekly injections create substantial peak-to-trough swings, and twice-weekly injections reduce that peak-to-trough variance by roughly 30%. Daily injection flattens the curve further still, getting closer to the body's natural production rhythm of around 6 to 7mg per day. The total weekly testosterone dose stays identical across all of these scenarios. The enzyme activity doesn't change. What changes is the spike, and the spike is what drives the symptoms.

Injection frequency is one driver, but the environment the enzyme lives in matters just as much.

Aromatase is concentrated in adipose tissue, meaning body fat is not just passive storage, it's an active conversion site. The gene expression of aromatase in fat tissue is driven upward by glucocorticoids, inflammatory cytokines like TNF-alpha, and a class of signaling molecules called class 1 cytokines. This creates a feedback loop where more body fat produces more aromatase, which produces more estrogen, which can promote further fat storage. Alcohol directly increases aromatase activity. Insulin resistance alters aromatase expression and also changes levels of something called SHBG, which is sex hormone-binding globulin, a protein that binds testosterone in the blood and limits how much of it is free and available for conversion. Chronic stress elevates cortisol, and cortisol drives aromatase expression through the same promoter pathway as glucocorticoids. Poor sleep elevates both cortisol and inflammatory cytokines. Genetics introduce individual variation in how much of this enzyme different people express at the same body fat percentage and dose.

When you stack all of these together, you can see that two men on identical doses can have very different estradiol levels and that the difference is rarely the dose itself.

Here is where the clinical trap forms. A man starts TRT on weekly injections, develops symptoms from the large estradiol peak, and the clinic adds anastrozole. Anastrozole is an aromatase inhibitor, which means it suppresses the enzyme directly rather than reducing the substrate load feeding it. The estradiol comes down. The symptoms improve. But now the man is on a drug that has a narrow therapeutic window, no FDA approval for use in men, and a downstream risk profile that deserves serious attention.

A randomized controlled trial published in the New England Journal of Medicine in 2013 studied 400 healthy men aged 20 to 50. Researchers suppressed natural testosterone production with a drug called goserelin and then gave the men controlled testosterone doses with or without anastrozole added to block aromatization. The goal was to isolate what estrogen and testosterone each do independently. What they found was that blocking aromatase, while testosterone was still present and measurable, produced significant declines in sexual desire and erectile function, with the sexual desire decline reaching a p-value below 0.001. Subcutaneous fat area increased two to three times in the estrogen-suppressed groups compared to groups that retained estrogen. The suppression of estrogen produced, in otherwise healthy men, the same body composition and sexual function changes that drive men to start TRT in the first place, just from the opposite direction.

Bone is where the long-term consequences accumulate. A double-blind randomized trial published in the Journal of Clinical Endocrinology and Metabolism in 2009 gave 69 men over age 60 either 1mg of anastrozole daily or a placebo for 12 months. Estradiol dropped approximately 20%, from around 15 to around 12 pg/mL. Spine bone mineral density decreased significantly in the anastrozole group, with a p-value of 0.0014. A 20% reduction in estradiol over one year produced measurable bone loss in older men. That is not a theoretical concern. It is a documented outcome.

The reason estrogen matters this much in men is that in bone, estradiol is more strongly associated with bone mineral density and bone turnover than testosterone itself is. Estrogen promotes vasodilation and has protective effects on vascular smooth muscle and the endothelium. Brain aromatase converts testosterone to estradiol locally, and that local conversion supports cognitive function and neuroprotection. Sexual desire and erectile function both depend on adequate estradiol, which is why the Finkelstein study found that blocking conversion while maintaining testosterone still degraded both.

So what does the practical pathway look like.

Start with an accurate measurement. The standard estradiol immunoassay test that most labs run can cross-react with other steroids circulating in men and produce readings that are higher than the actual estradiol level. The accurate test is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring estradiol in men. Once you have an accurate number, you have a real starting point. Target ranges used clinically are generally 20 to 35 pg/mL for standard TRT doses, with values up to 40 to 60 pg/mL sometimes acceptable at higher doses in men who are feeling well.

From there, the work is modifying the drivers. If you are injecting once weekly, moving to twice weekly reduces peak amplitude and flattens the estradiol curve without changing your total dose. If body fat is elevated, the fat itself is contributing aromatase capacity that no dose adjustment will fully overcome. Alcohol has a direct effect on the enzyme and removing it changes the biochemical environment. Managing insulin resistance, sleep quality, and chronic stress all work on the same inflammatory and hormonal pathways that regulate aromatase expression at the gene level.

An AI is not without a legitimate use case. There are men whose genetics produce high aromatase expression at lean body weights, reasonable doses, and frequent injection schedules, and where lifestyle modification has genuinely been optimized. For those men, a carefully managed AI may be appropriate. But that is the edge case, not the starting point.

The reason this matters beyond any individual protocol is that estrogen is not a side effect of testosterone therapy. It is a product of testosterone that your body depends on for bone, vasculature, brain function, and sexual health. Treating it like a waste product to be suppressed inverts the biology, and when you suppress it you do not eliminate symptoms, you trade one set of symptoms for another while adding long-term risks that compound quietly over months and years.

The enzyme was never the problem. The environment feeding the enzyme was.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness